Check-Cap

Company Overview

Snapshot

Founded in January 2005 by Yoav Kimchy, Check-Cap operates with 11–50 employees. The company has raised a total of $134.22 million across 15 funding rounds from 6 investors. A significant milestone for the company was its acquisition by MBody AI in September 2025.

Business overview

Check-Cap is a clinical-stage medical diagnostics company focused on redefining colorectal cancer (CRC) screening. The company's core product, C-Scan, is a patient-friendly, preparation-free, capsule-based screening technology that uses an ultra-low dose X-ray capsule and proprietary software to generate a 3D map of the colon. This non-invasive method aims to increase screening adherence by detecting polyps before they develop into colorectal cancer. Check-Cap operates within the Digital Medical Diagnostics and Medical Devices sectors, serving the healthcare industry and patients in markets such as the United States and Israel.

Strategic signal

In September 2025, Check-Cap was acquired by MBody AI. This acquisition signals a strategic consolidation within the digital health and medical diagnostics landscape, indicating a potential integration of Check-Cap's innovative colorectal cancer screening technology into a broader AI-driven health platform. For investors, this event represents a successful exit for Check-Cap and highlights the increasing value placed on non-invasive diagnostic solutions in the health tech market.

Company Intelligence Q&A

What was a significant corporate development for Check-Cap in September 2025?

In September 2025, Check-Cap was acquired by MBody AI.

What was the outcome of the proposed merger between Check-Cap and Nobul AI Corp?

In March 2024, Nobul AI Corp and Check-Cap Ltd entered into a definitive business combination agreement for a merger.

What strategic action did Check-Cap announce in June 2023?

In June 2023, Check-Cap announced a review of strategic alternatives and a reduction in its workforce.

When did Check-Cap initiate its U.S. pivotal trial?

Check-Cap announced the initiation of its U.S. pivotal trial in May 2022.

What regulatory approval did Check-Cap receive in March 2021?

In March 2021, the FDA approved Check-Cap’s investigational device exemption application, allowing it to begin a pivotal study of C-Scan in the United States.